Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Genmab
Genmab
Activities:
Ingredients
Research & Development
X
LinkedIn
Trending Articles
Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA
The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
Therapeutic: ensifentrine for chronic obstructive pulmonary disease
Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants
A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
Bringing biotech to the Baltics: the rise of Lithuania
Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues
The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA
Upcoming event
ISPE Singapore
28-30 August 2024 | Conference and exhibition | Singapore
See all
Related Content
Research & Development
Genmab finalises ProfoundBio acquisition
The $1.8bn acquisition allows Genmab exclusive access to ProfoundBio's clinical stage ADC Rina-S, as well as its ADC technology platforms
Regulatory
Tivdak receives US FDA approval for treating recurrent cervical cancer
The full approval of tisotumab vedotin will offer a treatment for patients with metastatic or recurrent cervical cancer exhibiting disease progression on or after chemotherapy
Drug Delivery
Partnership advances antibody therapies in immunology
Genmab and argenx have entered a multiyear collaboration, bringing together capabilities to jointly discover, develop and commercialise antibody therapies
Regulatory
ImaginAb announces supply agreement with Genmab
The non-exclusive worldwide agreement provides Genmab a license to use the company’s CD8 ImmunoPET imaging technology
Research & Development
Genmab and Synaffix enter into ADC license agreement
Genmab will be responsible for the research, development, manufacturing and commercialisation of any resulting ADC therapies
Manufacturing
Genmab chooses Ibex to take gene candidates to IND in 12 months
New contract extends the partnership between the Danish biotech company and Lonza
Research & Development
Personalised cancer treatment 2.0: new combination strategy developed
Tumours often comprise groups of cancer cells that show differential drug sensitivities, one of the reasons that initially effective treatments usually do not lead to long-term benefit in patients
Subscribe now